Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer




Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer

BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) — Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Robert Brown, MBA, CPA, as Chief Financial Officer.

Mr. Brown is a seasoned financial executive with deep expertise in strategic finance, operations, and growth planning for healthcare and medtech organizations. As an MBA and CPA, he brings the combination of strong financial acumen, regulatory rigor, and business leadership needed to guide high-growth companies in regulated industries.

Before joining Channel, Mr. Brown held senior financial roles across medtech and life sciences firms, where he built scalable financial infrastructure, led fundraising and M&A efforts, and aligned financial operations with commercialization goals.

“We’re thrilled to bring Robert on board,” said Nelson Whistance, President and Chief Executive Officer of Channel Medsystems. “His credentials and track record in financial leadership will be invaluable as we scale our operations and expand access to the Cerene® Cryotherapy Device.”

“I am honored to join Channel Medsystems at such a transformative moment,” said Robert Brown, MBA, CPA. “I believe deeply in Channel Medsystems’ mission to transform women’s healthcare. I look forward to supporting growth, strengthening financial operations, and helping advance broader access to safe and effective therapies.”

With Mr. Brown’s appointment, Channel Medsystems strengthens its executive team’s financial leadership to support sustained growth and strategic execution.

About Channel Medsystems
Channel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through the development and commercialization of its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide safe, effective, and convenient therapy for women suffering from heavy menstrual bleeding (HMB) and dysmenorrhea. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access, and empowering women with greater control over their care.

For more information, visit cerene.com and follow us on LinkedIn.

Media Contact:
Tara Murphy
Vice President, Marketing
Channel Medsystems
tmurphy@cerene.com                                                                                                 
215-620-3004

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65a78797-c385-4a5c-913b-5b17216e8d81

Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer




Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer

BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) — Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Robert Brown, MBA, CPA, as Chief Financial Officer.

Mr. Brown is a seasoned financial executive with deep expertise in strategic finance, operations, and growth planning for healthcare and medtech organizations. As an MBA and CPA, he brings the combination of strong financial acumen, regulatory rigor, and business leadership needed to guide high-growth companies in regulated industries.

Before joining Channel, Mr. Brown held senior financial roles across medtech and life sciences firms, where he built scalable financial infrastructure, led fundraising and M&A efforts, and aligned financial operations with commercialization goals.

“We’re thrilled to bring Robert on board,” said Nelson Whistance, President and Chief Executive Officer of Channel Medsystems. “His credentials and track record in financial leadership will be invaluable as we scale our operations and expand access to the Cerene® Cryotherapy Device.”

“I am honored to join Channel Medsystems at such a transformative moment,” said Robert Brown, MBA, CPA. “I believe deeply in Channel Medsystems’ mission to transform women’s healthcare. I look forward to supporting growth, strengthening financial operations, and helping advance broader access to safe and effective therapies.”

With Mr. Brown’s appointment, Channel Medsystems strengthens its executive team’s financial leadership to support sustained growth and strategic execution.

About Channel Medsystems
Channel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through the development and commercialization of its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide safe, effective, and convenient therapy for women suffering from heavy menstrual bleeding (HMB) and dysmenorrhea. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access, and empowering women with greater control over their care.

For more information, visit cerene.com and follow us on LinkedIn.

Media Contact:
Tara Murphy
Vice President, Marketing
Channel Medsystems
tmurphy@cerene.com                                                                                                 
215-620-3004

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65a78797-c385-4a5c-913b-5b17216e8d81

Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review




Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review

New release introduces unparalleled digital medical history and clinical intake capabilities, supporting hospitals, employers, individuals, families, and health insurers—and opens limited Showcase Partner slots for a forthcoming national TV appearance.

Aliso Viejo, CA, Nov. 20, 2025 (GLOBE NEWSWIRE) — Galacxia Inc., creator of the Life Backup Plan Interoperable Lifecare Platform, today announces a new version featuring a first-of-its-kind, comprehensive, standardized digital health patient workflow. The enhancement helps clinicians, hospitals, employers, individuals, families, caregivers, and health insurers collect robust medical and lifestyle information quickly. This improves safety, reduces delays, and strengthens decision-making across the entire care continuum.

Sandy Eulitt, founder and CEO of Galacxia Inc., works on the Life Backup Plan Interoperable Lifecare(TM) digital health platform.

The release coincides with Medicare Open Enrollment Season (October 15 through December 7) and the annual period when employers, hospitals, and health insurers finalize their benefit offerings for the coming year.

A comprehensive intake workflow that helps clinicians diagnose faster

Organizing the vital details clinicians most rely on: medications, surgical, family, and medical history, allergies, and symptoms, Life Backup Plan integrates with EHR systems, reducing healthcare workload and simplifying access to essential patient information.

“While recently recovering from cervical spine surgery, I used Life Backup Plan to check on me, medication tracking, and symptom monitoring.” reflected Sandy Eulitt, founder and CEO of Galacxia Inc. “Managing a post-operative infection, with numerous clinical visits, home health care, wound care, supply orders, medication changes, and nearly two emergency room visits, this new version extrapolates my personal experience into a clinically aligned system which gives providers the tools they need to deliver more connected care.”

Hospitals will benefit significantly from the enhancement. Through comprehensive post-discharge monitoring and reduced information gaps, Life Backup Plan helps organizations lower readmissions, strengthen JCAHO performance, improve care coordination, and reduce CMS penalties associated with preventable readmissions.

Clinician-approved approach to interoperability

“From a clinical operations standpoint, Life Backup Plan addresses a longstanding gap in healthcare: patient-driven interoperability,” said Dr. Allison Lamont, Chief Medical Officer of Life Backup Plan. “By aligning the platform with the standard intake information physicians rely upon, it improves the accuracy of clinical data, supports safer decision-making, and reduces inefficiencies across the system. It’s a practical, scalable solution that strengthens both care quality and continuity.”

Support for seniors, caregivers, and families—without limiting the platform’s reach

“In my work helping seniors choose Medicare coverage, I see how overwhelmed people of all ages feel—not because they lack ability, but because the healthcare system is so fragmented,” said Meredith Skurkey, a Medicare Advantage specialist. “Life Backup Plan is the first tool I’ve seen that brings medications, history, safety tools, and vital documents together in one secure, easy-to-use platform. It gives my clients clarity, confidence, and peace of mind—and helps them stay healthier and independent longer.”

Health insurance adjacent benefits

The platform reduces absenteeism and employee distraction by identifying and responding to illnesses and emergencies earlier. It also supports workers who care for aging parents or young children, resulting in improved productivity and fewer health and/or safety related disruptions.

Universal health and safety tool

Although the timing coincides with Open Enrollment, the platform remains universally beneficial for people of all ages. It supports anyone who may be by themselves at any time, including individuals living alone, outdoor enthusiasts, travelers, women, singles, and parents who want reassurance that their children arrived home safely. Whether someone is hanging Christmas lights, moving boxes, showering while home alone, or navigating safety risks that disproportionately affect women, the app provides a reliable safety net during falls, safety concerns, or medical emergencies.

Business Today Showcase Partner opportunity

Life Backup Plan will be featured in a “Maximizing the Healthcare Journey” segment on Business Today with Bill and Giuliana Rancic. The segment tapes in January, 2026, with the episode airing in March 2026. Galacxia Inc. is announcing a Showcase Partner Program for organizations that would like to be filmed on site and featured during the broadcast. Partners may also appear in short-form video reels, podcast content, social media, and related media packages. Interested organizations should contact Sandy Eulitt.

Official Business Today with Bill and Giuliana Rancic promotional artwork, provided for use in advance of the Life Backup Plan feature segment.

About Life Backup Plan by Galacxia, Inc

Life Backup Plan is a first-of-its-kind, interoperable digital health and safety platform built around the Five M’s of Health and Safety™: Monitoring, Medicine, Metrics, Money, and Membership. The platform provides early detection and rapid response for both illness and emergencies through intelligent check-ins, symptom tracking, medication logs, and passive alert escalation. These capabilities lower healthcare costs by identifying issues sooner, improving diagnostic speed, and enabling earlier intervention before complications develop. For emergent or non-emergent medical interaction, Life Backup Plan centralizes digital medical history, clinical intake data, allergies, family and surgical history, risk factors, and other essential health information in one secure, patient-managed system. This gives first responders, healthcare workers, and care teams immediate access to accurate, organized data that strengthens decision-making and improves care coordination across hospitals, outpatient care, home-based care, and recovery settings. Designed for people of all ages and lifestyles, Life Backup Plan supports individuals, families, aging in place, caregiving, disability support, post-discharge monitoring, women’s safety, dating and travel safety, outdoor recreation, and domestic violence and human trafficking prevention. The platform delivers health-insurance–adjacent benefits for employers by reducing absenteeism, minimizing avoidable health events, and supporting employees who care for aging parents or young children. Its comprehensive design helps hospitals, employers, insurers, and public agencies reduce preventable complications, lower costs, and improve safety, independence, and continuity of care for the people they serve.

Press inquiries

Life Backup Plan by Galacxia, Inc
https://www.lifebackupplan.com
Sandy Eulitt
founder@lifebackupplan.com
8588480860
49 El Prado Lane, Oceanside, CA 92058

A video accompanying this announcement is available at: https://www.youtube.com/embed/eNg74k-t2l4

Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review




Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review

New release introduces unparalleled digital medical history and clinical intake capabilities, supporting hospitals, employers, individuals, families, and health insurers—and opens limited Showcase Partner slots for a forthcoming national TV appearance.

Aliso Viejo, CA, Nov. 20, 2025 (GLOBE NEWSWIRE) — Galacxia Inc., creator of the Life Backup Plan Interoperable Lifecare Platform, today announces a new version featuring a first-of-its-kind, comprehensive, standardized digital health patient workflow. The enhancement helps clinicians, hospitals, employers, individuals, families, caregivers, and health insurers collect robust medical and lifestyle information quickly. This improves safety, reduces delays, and strengthens decision-making across the entire care continuum.

Sandy Eulitt, founder and CEO of Galacxia Inc., works on the Life Backup Plan Interoperable Lifecare(TM) digital health platform.

The release coincides with Medicare Open Enrollment Season (October 15 through December 7) and the annual period when employers, hospitals, and health insurers finalize their benefit offerings for the coming year.

A comprehensive intake workflow that helps clinicians diagnose faster

Organizing the vital details clinicians most rely on: medications, surgical, family, and medical history, allergies, and symptoms, Life Backup Plan integrates with EHR systems, reducing healthcare workload and simplifying access to essential patient information.

“While recently recovering from cervical spine surgery, I used Life Backup Plan to check on me, medication tracking, and symptom monitoring.” reflected Sandy Eulitt, founder and CEO of Galacxia Inc. “Managing a post-operative infection, with numerous clinical visits, home health care, wound care, supply orders, medication changes, and nearly two emergency room visits, this new version extrapolates my personal experience into a clinically aligned system which gives providers the tools they need to deliver more connected care.”

Hospitals will benefit significantly from the enhancement. Through comprehensive post-discharge monitoring and reduced information gaps, Life Backup Plan helps organizations lower readmissions, strengthen JCAHO performance, improve care coordination, and reduce CMS penalties associated with preventable readmissions.

Clinician-approved approach to interoperability

“From a clinical operations standpoint, Life Backup Plan addresses a longstanding gap in healthcare: patient-driven interoperability,” said Dr. Allison Lamont, Chief Medical Officer of Life Backup Plan. “By aligning the platform with the standard intake information physicians rely upon, it improves the accuracy of clinical data, supports safer decision-making, and reduces inefficiencies across the system. It’s a practical, scalable solution that strengthens both care quality and continuity.”

Support for seniors, caregivers, and families—without limiting the platform’s reach

“In my work helping seniors choose Medicare coverage, I see how overwhelmed people of all ages feel—not because they lack ability, but because the healthcare system is so fragmented,” said Meredith Skurkey, a Medicare Advantage specialist. “Life Backup Plan is the first tool I’ve seen that brings medications, history, safety tools, and vital documents together in one secure, easy-to-use platform. It gives my clients clarity, confidence, and peace of mind—and helps them stay healthier and independent longer.”

Health insurance adjacent benefits

The platform reduces absenteeism and employee distraction by identifying and responding to illnesses and emergencies earlier. It also supports workers who care for aging parents or young children, resulting in improved productivity and fewer health and/or safety related disruptions.

Universal health and safety tool

Although the timing coincides with Open Enrollment, the platform remains universally beneficial for people of all ages. It supports anyone who may be by themselves at any time, including individuals living alone, outdoor enthusiasts, travelers, women, singles, and parents who want reassurance that their children arrived home safely. Whether someone is hanging Christmas lights, moving boxes, showering while home alone, or navigating safety risks that disproportionately affect women, the app provides a reliable safety net during falls, safety concerns, or medical emergencies.

Business Today Showcase Partner opportunity

Life Backup Plan will be featured in a “Maximizing the Healthcare Journey” segment on Business Today with Bill and Giuliana Rancic. The segment tapes in January, 2026, with the episode airing in March 2026. Galacxia Inc. is announcing a Showcase Partner Program for organizations that would like to be filmed on site and featured during the broadcast. Partners may also appear in short-form video reels, podcast content, social media, and related media packages. Interested organizations should contact Sandy Eulitt.

Official Business Today with Bill and Giuliana Rancic promotional artwork, provided for use in advance of the Life Backup Plan feature segment.

About Life Backup Plan by Galacxia, Inc

Life Backup Plan is a first-of-its-kind, interoperable digital health and safety platform built around the Five M’s of Health and Safety™: Monitoring, Medicine, Metrics, Money, and Membership. The platform provides early detection and rapid response for both illness and emergencies through intelligent check-ins, symptom tracking, medication logs, and passive alert escalation. These capabilities lower healthcare costs by identifying issues sooner, improving diagnostic speed, and enabling earlier intervention before complications develop. For emergent or non-emergent medical interaction, Life Backup Plan centralizes digital medical history, clinical intake data, allergies, family and surgical history, risk factors, and other essential health information in one secure, patient-managed system. This gives first responders, healthcare workers, and care teams immediate access to accurate, organized data that strengthens decision-making and improves care coordination across hospitals, outpatient care, home-based care, and recovery settings. Designed for people of all ages and lifestyles, Life Backup Plan supports individuals, families, aging in place, caregiving, disability support, post-discharge monitoring, women’s safety, dating and travel safety, outdoor recreation, and domestic violence and human trafficking prevention. The platform delivers health-insurance–adjacent benefits for employers by reducing absenteeism, minimizing avoidable health events, and supporting employees who care for aging parents or young children. Its comprehensive design helps hospitals, employers, insurers, and public agencies reduce preventable complications, lower costs, and improve safety, independence, and continuity of care for the people they serve.

Press inquiries

Life Backup Plan by Galacxia, Inc
https://www.lifebackupplan.com
Sandy Eulitt
founder@lifebackupplan.com
8588480860
49 El Prado Lane, Oceanside, CA 92058

A video accompanying this announcement is available at: https://www.youtube.com/embed/eNg74k-t2l4

23andMe Research Institute Helps Reconnect African Diaspora to Their Roots with Release of 250+ High-Resolution African Genetic Groups




23andMe Research Institute Helps Reconnect African Diaspora to Their Roots with Release of 250+ High-Resolution African Genetic Groups

Major Scientific Expansion Provides the Most Detailed Look at African Ancestry on the Market, Helping to Bypass Historical ‘Brick Walls’ for Individuals with African Heritage

PALO ALTO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) — For millions of Americans in the African diaspora, genealogical ties and records were severed by the transatlantic slave trade, creating a ‘brick wall’ for those seeking to know their full heritage. Today, 23andMe Research Institute announced a landmark expansion of its genetic ancestry reports and features, unveiling more than 250 high-resolution Genetic Groups across Africa. This significant update provides members with African heritage the most detailed and scientifically rigorous look at their roots currently available on the market, further establishing 23andMe Research Institute as the leader in detailed genetic ancestry.

“This is more than a scientific update; it’s a new chapter in the right to know your own story,” said Steven Micheletti, Ph.D, senior scientist of population genetics at 23andMe Research Institute. “For too long, individuals of African descent have hit a ‘brick wall’ in traditional genealogy, their paper trails erased by time and history. This update uses our advancements in the field of genetics to help bypass that wall. Seeing your West African ancestry trace to one of 57 specific groups in Nigeria, for example, can be a profound experience. We are incredibly proud to apply our science to help facilitate these powerful discoveries that restore human connection and a piece of lost heritage.”

The update represents an improvement by a factor of 10, moving from 25 African Genetic Groups to more than 250 — significantly improving the accuracy and specificity of ancestry results for the continent. More than 80% of 23andMe’s Black and African American customers on the latest V5 genotyping chip will now see matches to one or more of these high-resolution genetic groups, offering a new, more specific starting point for their ancestral journey.

Prior to this expansion, the organization’s ancestry reports and features already held one of the highest ratings from the International Society of Genetic Genealogy for “overall accuracy and sophistication of the biogeographical ancestry analysis.”

Powered by Community-Driven Science

This landmark update was made possible by the willing participation of thousands of research-consented 23andMe Research Institute members with documented ancestry in Africa. Their participation enabled the development of a more inclusive and detailed map of human history for everyone.

The expanded groups, which span Eastern, Middle, Southern, and Western Sub-Saharan Africa, include:

• 57 Nigerian genetic groups
• 44 Angolan & Congolese genetic groups
• 40 Ethiopian & Eritrean genetic groups
• 32 Ghanaian, Liberian & Sierra Leonean genetic groups
• And a total of 28 Somali, 22 Senegambian & Guinean, and 9 Sudanese genetic groups, among others.

While the vast majority of Black and African American 23andMe Research Institute members on the latest genotyping chip will receive one or more of these new groups, there is more work to do. The organization is committed to expanding its reference panels and refining its industry-leading science to bring this level of detail to all members.

23andMe Research Institute Continues to Innovate Genetic Ancestry

The expansion of African Genetic Groups follows closely on the heels of the organization’s major update to Ancestry Composition.

The Ancestry Composition update provided:

• Unmatched granularity in ancestry percentages with 33 new populations in Europe and 6 new populations in the Americas. With these two updates, there are now a total of more than 4,500 populations for members to explore.
• The platform’s algorithm was updated to eliminate “Broadly” and “Unassigned” categories in the default results view.
• A new state-of-the-art DNA phasing pipeline reduces errors and gives a more accurate estimate of genetic ancestry percentages, even if ancestry isn’t from Europe or the Americas.

The Ancestry Composition update (Version Seven) was particularly focused on improving two major metrics: precision and recall. Precision confirms how often a piece of DNA is correctly predicted from a specific population. Recall confirms how much DNA from a specific population is correctly identified. Working to maximize both precision and recall is critical to making Ancestry Composition and other ancestry features as accurate as possible.

The update improved the underlying science behind member reports and features including, Ancestry Composition, Ancestry Timeline, Parental Inheritance, and DNA Painting, among others, ensuring 23andMe Research Institute continues to deliver the most precise and reliable ancestry results in the industry.

About 23andMe Research Institute

23andMe Research Institute is a nonprofit medical research organization that enables people everywhere to access their genetic information, learn about themselves and participate in the world’s largest crowdsourced research initiative. The Institute aims to be the world’s most significant contributor to scientific advancement, uniting people with the common goal of improving health and deepening our understanding of DNA — the code of life.

Media Contact:
press@23andMe.com
Catherine Afarian
23andMe Research Institute
408.656.8872
catherine.afarian@23andme.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d399aa86-54bf-4897-85d9-85334b40b37c

Hydreight Technologies Ranked #77 Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™




Hydreight Technologies Ranked #77 Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

VANCOUVER, British Columbia and LAS VEGAS, Nov. 20, 2025 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) today announced it ranked No. 77 on the 2025 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

Hydreight’s Chief Executive Officer, Shane Madden, attributes the Company’s growth to the continued expansion of its compliant national telehealth and pharmacy infrastructure, and the rapid onboarding of partners to its VSDHOne direct-to-consumer (D2C) platform, which enables healthcare and wellness brands to launch nationwide in days instead of months. Madden said:

“Our revenue growth reflects one thing — the demand for a compliant, scalable, technology-driven healthcare infrastructure in the United States. We’re proud to see Hydreight recognized among the fastest-growing companies in North America. This ranking validates the work our team has done building a nationwide medical, pharmacy, and telehealth network that lets partners scale safely, responsibly, and profitably.”

“This year’s rankings highlight both enduring leadership and breakthrough momentum,” said Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader and partner, Deloitte Tax LLP. “More than half of the winners are prior honorees, yet the majority of the top ten are first-time entrants — demonstrating the staying power of established leaders alongside the accelerating growth of new innovators across key sectors. As in previous years, private companies continue to dominate, underscoring the agility that private enterprises bring to competitive markets, enabling the exceptional triple and quadruple digit growth reflected in these rankings.”

Hydreight previously ranked #56 on the 2024 Deloitte Technology Fast 500™ and #9 on Deloitte’s 2024 Technology Fast 50™ (Canada), and was recognized again in 2025 as one of Canada’s Technology Fast 50™ award winners.

Overall, 2025 Technology Fast 500 companies achieved revenue growth ranging from 122% to 29,738% over the three-year period, with an average growth rate of 1,079%.

About the 2025 Deloitte Technology Fast 500™

Now in its 31st year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal-year revenue growth from 2021 to 2024.

To be eligible, companies must own proprietary intellectual property or technology that contributes significantly to operating revenue; have base-year revenues of at least US$50,000 and current-year revenues of at least US$5 million; have been in business for a minimum of four years; and be headquartered in North America.

On behalf of the Board of Directors

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

Contact
Email: ir@hydreight.com; Telephone: (702) 970-8112

Hydreight Technologies Inc Ranked Number 25 Technology Fast 50 winners 2025 | Deloitte Canada

Hydreight Technologies Inc Ranked Number 77 Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

About Hydreight Technologies Inc.

Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 200 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

About VSDHOne – Direct to Consumer Platform

Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Johns Hopkins Health Plans Welcomes Inova Health To Medicare Advantage Network




Johns Hopkins Health Plans Welcomes Inova Health To Medicare Advantage Network

Relationship Enhances Care Access as Advantage MD Expands Virginia Service Area

HANOVER, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) — Effective Jan. 1, 2026, Virginia-based Inova Health will be an in-network provider for Johns Hopkins Advantage MD, a Medicare Advantage plan from Johns Hopkins Health Plans. With Medicare’s Annual Enrollment Period underway, residents have until Dec. 7 to select coverage for 2026.

The new relationship supplements Advantage MD’s regional expansion, as the plan will now serve Fairfax County, Loudoun County, Prince William County, and the Cities of Alexandria, Manassas, and Manassas Park. The plan has served Medicare beneficiaries in Arlington County, Fairfax City and Falls Church City since 2024.

In addition to affordable coverage, the expanded network provides Advantage MD members access to Inova Health’s network of hospitals, outpatient services, and long-term care facilities, throughout Northern Virginia and parts of Maryland.

“We’re thrilled for the opportunity to serve the health care needs of the Medicare-eligible population in Northern Virgina and provide our Advantage MD members access to Inova Health’s world-class facilities and provider network,” said J.P. Holland, President and CEO of Johns Hopkins Health Plans.

Medicare-eligible Virginians will not only enjoy ease of access to the region’s top health system in Inova, but all the benefits of Advantage MD membership, including trusted doctors, high-quality care and affordable coverage. Advantage MD and Inova Health share a strong history of commitment to the communities we serve and are proud to be working together to expand access to high-quality care while uplifting the health care of Medicare-eligible Virginia residents.

“We are pleased to expand access to Inova’s clinical excellence and comprehensive care for Johns Hopkins Health Plans members in Northern Virginia,” said J. Stephen Jones, MD, FACS, President and CEO of Inova Health. “This collaboration reflects our shared commitment to ensuring our community has access to high-quality, patient-centered Inova care when and where they need it.”

Inova Health is the leading nonprofit health care provider in Northern Virginia and the Washington, D.C., metropolitan area with an integrated network of hundreds of care sites throughout Northern Virginia and Maryland. Inova was named by Press Ganey the 2025 “Health System of the Year” for leading in clinical excellence, patient experience and innovation. Its flagship hospital, Inova Fairfax Hospital, has been ranked #1 Best Hospital in both Virginia and Greater Washington by U.S. News & World Report for five consecutive years.

“Like Advantage MD, Inova shares our commitment to prioritizing the member and patient experience,” said Lori Rund, Vice President, Medicare Advantage, at Johns Hopkins Health Plans. “We look forward to working with Inova to deliver affordable, quality health care to even more members in Virginia.”

About Johns Hopkins Health Plans 

As a part of Johns Hopkins Medicine, Johns Hopkins Health Plans administers a range of physician-sponsored health plans managing more than $3 billion in annual premiums and serving more than 400,000 members. Johns Hopkins Health Plans’ robust network of providers includes Johns Hopkins Medicine physicians and providers, regional clinics and many other top-tier providers. Johns Hopkins Health Plans administers the US Family Health Plan for active-duty family members, military retirees and their families, Employer Health Programs, Priority Partners (Maryland’s largest Medicaid plan with co-owner Maryland Community Health System) and Advantage MD Medicare Advantage plans. It advocates for its members and fosters collaboration with providers to help achieve optimal health. Through its Johns Hopkins HealthCare Solutions business, Johns Hopkins Health Plans also offers the world’s leading population health analytics software, the Johns Hopkins ACG^® System, used by commercial and government health entities and employers worldwide. Learn more at hopkinshealthplans.org.

Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference




Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14^th Annual Discovery One-on-One Investor Conference by hosting 1×1 investor meetings.

Conference Details
Date: December 4, 2025
Location: New York, New York
Format: 1×1 meetings (contact your Benchmark Representative)

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

Shattuck Labs to Participate in Upcoming December Investor Conferences




Shattuck Labs to Participate in Upcoming December Investor Conferences

AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025.

Conference Details

Conference: Piper Sandler 37^th Annual Healthcare Conference
Format: Presentation and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Presentation Date: Dec 2, 2025
Time: 10:10 AM EST
Location: New York, NY
Webcast link: HERE

Conference: Evercore ISI 8^th Annual HealthCONx Conference
Format: Fireside chat with Umer Raffat and Jonathan Miller, Ph.D. and one-on-one meetings (Dec 3-4)
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Fireside Chat Date: Dec 4, 2025
Time: 8:20 AM EST
Location: Coral Gables, FL
Webcast link: HERE

A replay of the presentations from the Piper Sandler 37^th Annual Healthcare Conference and the Evercore ISI 8^th Annual HealthCONx Conference will be available on the Events and Presentations section of the Company’s website. A replay of the webcasts will remain archived for up to 30 days following the presentation date.

About SL-325

SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced humanized immunoglobin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)




Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission (EC) has granted marketing authorizations in the European Economic Area (EEA) for Gobivaz®, Alvotech’s biosimilar to Simponi® (golimumab).

The authorizations cover Gobivaz® 50 mg/0.5 mL and 100mg/mL in both pre-filled syringe with passive needle safety guard and autoinjector formats, for the treatment of adults with rheumatoid arthritis in combination with methotrexate, psoriatic arthritis with or without methotrexate, axial spondyloarthritis, ulcerative colitis and for the treatment of juvenile idiopathic arthritis in children 2 years of age and older in combination with methotrexate. The approvals apply across the European Economic Area. The EC approval follows the positive opinion issued in September by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

“This milestone marks the second biosimilar to receive approval through our partnership with Advanz Pharma and further strengthens the commercial presence we are building in Europe. As the first biosimilar to Simponi® (golimumab) to gain approval in the European market, we are committed to expanding access to high quality biologic medicines for people living with immune-mediated diseases while providing value to healthcare systems throughout the region” said Robert Wessman, Chairman and Chief Executive Officer of Alvotech.

“We welcome the EC approval of Gobivaz®, an important milestone in our partnership with Alvotech. Expanding access to high-quality biosimilars is central to Advanz Pharma’s mission, and this approval enables us to offer patients across Europe a valuable new treatment option for immune-mediated diseases.” said Steffen Wagner, Chief Executive Officer, Advanz Pharma.

Under the partnership between Alvotech and Advanz Pharma, Alvotech is responsible for the development and commercial supply of Gobivaz®, while Advanz Pharma holds the registration and exclusive commercialization rights in the EEA and the UK.

The EC approval of Gobivaz® was based on a totality of evidence, including analytical and clinical data. In April 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between its biosimilar candidate AVT05 and the reference product Simponi® in patients with moderate to severe rheumatoid arthritis (clintrials.gov/study/NCT05842213). In November 2023, Alvotech announced positive topline results from a pharmacokinetic study which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult participants (clintrials.gov/study/NCT05632211).

About AVT05
AVT05 (golimumab) has been approved as Golimumab BS (golimumab) in Japan and as Gobivaz (golimumab) in the European Economic Area. Dossiers are under review in multiple countries globally.  Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha). Elevated TNF alpha levels have been implicated in several chronic inflammatory diseases such as rheumatoid arthritis [1].

Sources
[1] Simponi product information

Use of Trademarks
Simponi^® is a registered trademark of Johnson & Johnson. Gobivaz® is a trademark of Advanz Pharma.

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has established a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

About Advanz Pharma
Partner of choice in specialty, hospital, and rare disease medicines. Advanz Pharma is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma’s product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity.

Alvotech Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Advanz Pharma Forward Looking Statements
Certain statements in this press release are forward-looking statements. These statements may be identified by words such as “anticipate”, “expectation”, “belief’, “estimate”, “plan”, “target”, “project”, “will”, “may”, “should” or “forecast” and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma’s markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice.

MEDIA CONTACTS

Alvotech Global Communications and Investor Relations
Benedikt Stefansson
alvotech.ir@alvotech.com

Advanz Pharma Global Corporate Communications
Courtney Baines
courtney.baines@advanzpharma.com